Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

NCT01349790 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Thrombocytopenia

Interventions

DRUG: NewGam

Sponsor

Octapharma